Pfizer Vfend Cardiac Safety Studies Needed For Esophageal Candida Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Approval of Pfizer’s Vfend for treatment of esophageal candidiasis depends on completion of cardiac studies to rule out an unacceptable risk of QTc prolongation, review documents for the triazole antifungal indicate.